Hospitalization burden and survival among older glioblastoma patients

Neuro-Oncology

Volumn 16, Issue 11, 2014, Pages 1530-1540

  Arvold, Nils D ^a   Wang, Yun ^b   Zigler, Cory ^b   Schrag, Deborah ^c   Dominici, Francesca ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Elderly; Glioblastoma; Hospitalization; Survival; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

AGED; ARTICLE; BLACK PERSON; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA ANALYSIS; DEATH; FEMALE; GLIOBLASTOMA; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL TIME; BRAIN NEOPLASMS; FOLLOW UP; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HOSPITALIZATION; HUMANS; MALE; PROGNOSIS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL RATE;

EID: 84922160495     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou060     Document Type: Article

References (35)

1. Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002;4(4):278-299.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
3. Iwamoto FM, Reiner AS, Panageas KS, et al. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64(6):628-634.
4. Barnholtz-Sloan JS, Maldonado JL, Williams VL, et al. Racial/ethnic differences in survival among elderly patients with a primary glioblastoma. J Neurooncol. 2007;85(2):171-180.
5. Malmström A, Gronberg BG, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916-926.
6. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707-715.
7. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583-1588.
8. Gállego Pérez-Larraya J, Ducray F, Chinot O, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011;29(22):2050-2055.
9. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527-1535.
10. Barnholtz-Sloan JS, Williams VL, Maldonado JL, et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg. 2008;108(4):642-648.
11. Zhang B, Nilsson ME, Prigerson HG. Factors important to patients' quality of life at the end of life. Arch Intern Med. 2012;172(15):1133-1142.
12. Townsend J, Frank AO, Fermont D, et al. Terminal cancer care and patients' preference for place of death: a prospective study. Br Med J. 1990;301(6749):415-417.
13. Sizoo EM, Pasman HR, Buttolo J, et al. Decision-making in the end-of-life phase of high-grade glioma patients. Eur J Cancer. 2012;48(2):226-232.
14. Paszat L, Laperriere N, Groome P, et al. A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51(1):100-107.
15. National Cancer Institute. Surveillance, Epidemiology and End Results. Available at: http://seer.cancer.gov/about/overview.html. Accessed February 11, 2014.
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
17. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
18. Darefsky AS, King JT Jr, Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer. 2012;118(8):2163-2172.
19. Williams MV. A requirement to reduce readmissions: take care of the patient, not just the disease. JAMA. 2013;309(4):394-396.
20. Vuorinen V, Hinkka S, Färkkilä M, et al. Debulking or biopsy of malignant glioma in elderly people-a randomised study. Acta Neurochir. 2003;145(1):5-10.
21. Smith AK, McCarthy EP, Paulk E, et al. Racial and ethnic differences in advance care planning among patients with cancer: impact of terminal illness acknowledgment, religiousness, and treatment preferences. J Clin Oncol. 2008;26(25):4131-4137.
22. Stupp R. Elderly GBM patients-temozolomide or radiotherapy? A perspective. Presented at EORTC EANO Conference, Trends in Central Nervous System Malignancies, Bucharest, Romania, 2011. Available at: http://eccamsterdam2013.ecco-org.eu/Home/Events/Pastconferences/EORTC-EANO/Presentations.aspx. Accessed February 11, 2014.
23. Laperriere N, Weller M, Stupp R, et al. Optimal management of elderly patients with glioblastoma. Cancer Treat Rev. 2013;39(4):350-357.
24. Brooks GA, Li L, Sharma DB, et al. Regional variation in spending and survival for older adults with advanced cancer. J Natl Cancer Inst. 2013;105(9):634-642.
25. Pace A, Di Lorenzo C, Capon A, et al. Quality of care and rehospitalization rate in the last stage of disease in brain tumor patients assisted at home: a cost effectiveness study. J Palliat Med. 2012;15(2):225-227.
26. Guilfoyle MR, Weerakkody RA, Oswal A, et al. Implementation of neuro-oncology service reconfiguration in accordance with NICE guidance provides enhanced clinical care for patients with glioblastoma multiforme. Br J Cancer. 2011;104(12):1810-1815.
27. Centers for Medicare & Medicaid Services. New Physician Specialty Code for Hospice and Palliative Care. Available at: http://www.cms. gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R1715CP.pdf. Accessed February 11, 2014.
28. Song Y, Skinner J, Bynum J, et al. Regional variations in diagnostic practices. N Engl J Med. 2010;363(2):45-53.
29. Jagsi R, Abrahamse P, Hawley ST, et al. Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data. Cancer. 2012;118(2):333-341.
30. Du X, Freeman JL, Warren JL, et al. Accuracy and completeness of Medicare claims data for surgical treatment of breast cancer. Med Care. 2000;38(7):719-727.
31. Davidoff AJ, Shaffer T, Erten MZ, et al. Use and spending on antineoplastic therapy for Medicare beneficiaries with cancer. Med Care. 2013;51(4):351-360.
32. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005;11(19 Pt 1):6767-6771.
33. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
34. Park HS, Gross CP, Makarov DV, et al. Immortal time bias: a frequently unrecognized threat to the validity in the evaluation of postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(5):1365-1373.
35. Oberndorfer S, Lindeck-Pozza E, Lahrmann H, et al. The end-of-life hospital setting in patients with glioblastoma. J Palliat Med. 2008;11(1):26-30.